Zacks Investment Research on MSN
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
Halozyme Therapeutics HALO reported third-quarter 2025 adjusted earnings of $1.72 per share, which beat the Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback